Literature DB >> 10208700

Diagnosis and management of gout.

J R Pittman1, M H Bross.   

Abstract

Gout is a disease resulting from the deposition of urate crystals caused by the overproduction or underexcretion of uric acid. The disease is often, but not always, associated with elevated serum uric acid levels. Clinical manifestations include acute and chronic arthritis, tophi, interstitial renal disease and uric acid nephrolithiasis. The diagnosis is based on the identification of uric acid crystals in joints, tissues or body fluids. Treatment goals include termination of the acute attack, prevention of recurrent attacks and prevention of complications associated with the deposition of urate crystals in tissues. Pharmacologic management remains the mainstay of treatment. Acute attacks may be terminated with the use of nonsteroidal anti-inflammatory agents, colchicine or intra-articular injections of corticosteroids. Probenecid, sulfinpyrazone and allopurinol can be used to prevent recurrent attacks. Obesity, alcohol intake and certain foods and medications can contribute to hyperuricemia. These potentially exacerbating factors should be identified and modified.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208700

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  17 in total

Review 1.  Rheumatology: 2. What laboratory tests are needed?

Authors:  K Shojania
Journal:  CMAJ       Date:  2000-04-18       Impact factor: 8.262

Review 2.  Common laboratory tests for rheumatological disorders: how do they help the diagnosis?

Authors:  Esha Das Gupta
Journal:  Malays Fam Physician       Date:  2009-08-31

Review 3.  Management of acute and chronic gouty arthritis: present state-of-the-art.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  The Dietary Fructose:Vitamin C Intake Ratio Is Associated with Hyperuricemia in African-American Adults.

Authors:  Zihe Zheng; Jane L Harman; Josef Coresh; Anna Köttgen; Mara A McAdams-DeMarco; Adolfo Correa; Bessie A Young; Ronit Katz; Casey M Rebholz
Journal:  J Nutr       Date:  2018-03-01       Impact factor: 4.798

5.  Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.

Authors:  H Ralph Schumacher; Judith A Boice; David I Daikh; Saurabh Mukhopadhyay; Kerstin Malmstrom; Jennifer Ng; Guillermo A Tate; Javier Molina
Journal:  BMJ       Date:  2002-06-22

6.  Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.

Authors:  Daniel Hill-McManus; Elena Soto; Scott Marshall; Steven Lane; Dyfrig Hughes
Journal:  Br J Clin Pharmacol       Date:  2017-10-10       Impact factor: 4.335

Review 7.  Uric acid changes in urine and plasma: an effective tool in screening for purine inborn errors of metabolism and other pathological conditions.

Authors:  R E Simoni; L N L Ferreira Gomes; F B Scalco; C P H Oliveira; F R Aquino Neto; M L Costa de Oliveira
Journal:  J Inherit Metab Dis       Date:  2007-05-19       Impact factor: 4.982

8.  A case of ochronosis with gout and Monckeberg arteries.

Authors:  Hadi Karimzadeh; Negin Mohtasham; Mansoor Karimifar; Mansour Salesi; Zahra Sayed Bonakdar
Journal:  Rheumatol Int       Date:  2009-02-27       Impact factor: 2.631

9.  Functional metabolite assemblies-a review.

Authors:  Ruth Aizen; Kai Tao; Sigal Rencus-Lazar; Ehud Gazit
Journal:  J Nanopart Res       Date:  2018-05-01       Impact factor: 2.253

10.  Patient and clinical characteristics associated with gout flares in an integrated healthcare system.

Authors:  Nazia Rashid; Gerald D Levy; Yi-Lin Wu; Chengyi Zheng; River Koblick; T Craig Cheetham
Journal:  Rheumatol Int       Date:  2015-05-20       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.